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Abstract 
Objective: This study aims to study the prognostic impact of LV function on mortality and 
examine the effect of age on the prognostic value of left ventricular function. 
Methods: We examined the Myocardial Ischaemia National Audit Project (MINAP) registry 
(2006-2010) data with a mean follow up of 2.1 years. LV function was categorized into good 
(ejection fraction (EF) ≥50%), moderate (EF 30-49%) and poor (EF <30%) categories. Cox-
proportional hazards models were constructed to examine the prognostic significance of LV 
function in different age groups (<65, 65-74, 75-84 and ≥85 years) on all-cause mortality 
adjusting for baseline variables.   
Results: Of 424,848 patients, LV function data available for 123,609. Multiple imputations 
were used to impute missing values of LV function and the final sample for analyses were 
drawn from 414,305. After controlling for confounders, 339,887 participants were included 
in the regression models.  For any age group, mortality was higher with worsening degree of 
LV impairment. Increased age reduced the adverse prognosis associated with reduced LV 
function (hazard ratios (HRs) of death comparing poor LV function to good LV function 
were 2.11 95%CI 1.88-2.37 for age <65 years and 1.28 95%CI 1.20-1.36 for age ≥85 years. 
Older patients had a high mortality risk even in those with good LV function. HRs of 
mortality for ≥85 compared to <65 years (HR=1.00) within good, moderate and poor ejection 
fractions groups were 5.89, 4.86 and 3.43, respectively.   
Conclusions: In patients with ACS, clinicians should interpret the prognostic value of LV 
function taking into account patient’s age.  
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Introduction 
 Between one-third and a half of patients who present with an acute coronary 
syndrome (ACS) are left with left ventricular systolic dysfunction (LVSD).1  LVSD after 
ACS is a strong predictor of mortality and re-hospitalization2-4 even in patients who receive 
primary percutaneous coronary intervention5 with addition of LVEF to the TIMI 
(Thrombolysis in Myocardial Infarction) risk score improving the prediction of in-hospital 
death among ACS patients.6 
 Rates of LVSD following ACS that have been reported through analysis of clinical 
trials vary  from 12.6% to 36.6% depending on the mode, definition and timing of left 
ventricular assessment.2,7-9 However, these trials have highly selective cohorts where elderly 
patients with multiple co-morbidities may be excluded with such older patients  more likely 
to have LVSD.5 The relation between age, LVEF and mortality following ACS is itself less 
clear considering that increased age itself confers a poor prognosis following an ACS10,11 and 
that age-related left ventricular remodeling may worsen outcomes.12 Therefore, we aim to 
study the prevalence of LV dysfunction in an unselected national ‘real-world’ ACS cohort 
from the Myocardial Ischaemia National Audit Project (MINAP) stratified by age and 
investigate whether the prognostic significance of LV function in patients with ACS varies by 
age. 
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Methods 
Study design 
 The Myocardial Ischaemia National Audit Project (MINAP) was set up in England 
and Wales in 1999 to examine the quality of management of acute myocardial infarction.13,14  
This national registry includes patients admitted with ACS from 230 NHS hospital Trusts in 
England and Wales.15 All hospitals use a standardized data collection form with pre-specified 
definitions for all the variables. The MINAP uses a secure electronic data entry transmission 
and analysis system developed by the Central Cardiac Audit Database group16 which is part 
of the NHS Information Centre for Health and Social Care.  The current study obtained the 
ethical approval from the Faculty of Medicine & Health Sciences Research Ethics 
Committee, University of East Anglia and the investigators had no access to patient 
identifiers.17 
Cohort profile 
 In this paper, we included patients with an acute coronary syndrome (ACS) admitted 
between January 2006 and December 2010.  Patients included had received a final diagnosis 
of any type of ACS including ST elevation myocardial infarction (STEMI), non-ST elevation 
myocardial infarction (NSTEMI) and unstable angina, and these patients were followed up 
until date of death or up to 31 August 2011.  The final diagnosis, based on clinical assessment 
and investigations, was made by a senior member of the medical staff.   
 The original data set consisted of 424,848 participants and data on LVEF were only 
available for 123,609 participants (Supplementary Figure 1).  Comparison of participant 
characteristics for those who had values for LVEF and those who did not have values for 
LVEF are shown in Supplementary Table 1.  Because of the degree of missing data multiple 
imputations by chained equations were used to account for missing data.  Previous imputation 
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analyses within MINAP have not significantly altered effect sizes18 and the missing data is 
random and does not affect the validity of the analyses.19 
Study variables 
 LVEF for each participant was measured by echocardiography during the index 
hospital admission.  Good, moderate and poor LV function were defined as LVEF of ≥50%, 
30-49% and <30%, respectively.  
 For this analysis, age, sex, body mass index (BMI), smoking status (current smoker or 
ex-/non-smoker), hyperlipidemia, hypertension, co-morbidities (diabetes, myocardial 
infarction, angina, heart failure, stroke, chronic obstructive pulmonary disease (COPD), 
chronic renal failure, peripheral vascular disease (PVD)), prior cardiac interventions 
(percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)), 
biochemical results at the time of admission with the index ACS event (quartiles of peak 
troponin I (cutoffs 0.6, 4.12 and 21.35 ng/ml) or T (cutoffs 0.17, 0.68 and 2.6 g/dl)), 
admission medications (ACE inhibitor, beta blocker, statins, aspirin, clopidogrel), diagnosis, 
discharge medications (as above) and use of  angiography during the index admission were 
chosen as potentially prognostic co-variates in the regression models described below.  
Definitions for variables are pre-defined by MINAP and are available on their website 
(http://www.ucl.ac.uk/nicor/audits/minap/dataset). 
 We categorized final diagnosis into ST-segment elevation myocardial infarction 
(STEMI) and other acute coronary syndromes (non-ST elevation myocardial infarction (Non-
STEMI), troponin negative acute coronary syndrome, threatened myocardial infarction and 
myocardial infarction (unconfirmed)). 
Outcome ascertainment  
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 MINAP is linked to the Office for National Statistics' (ONS) registry and uses each 
patient's unique NHS number to obtain regular mortality updates.  The main outcome of the 
analysis in this study was 30-day mortality. 
Statistical methods 
 All analyses were performed in Stata SE, version 13.0 (Stata, College Station, Texas).  
 Multiple imputations by chained equations were used to account for missing data with 
ten imputed datasets.  All variables were included in the imputations model aside from those 
which led to failed convergence.  These variables were omitted from the imputations but 
were kept as passive variables (renal disease, admission clopidogrel use, discharge 
clopidogrel use and diagnosis) which were used in the sensitivity analysis.   
 The frequency distribution of the baseline characteristics and 30 day mortality 
outcomes of patients were presented for the first imputed dataset according to the LV 
function.  Statistical comparisons for significant baseline differences were performed using 
one way ANOVA (continuous variables) or chi-squared test (categorical variables). Age was 
categorized into four strata (<65, 65-74, 75-84 and ≥85 years). The prevalence of poor LV 
function according to age strata was evaluated graphically.   
 Odds ratios for 30-day mortality associated with LV function and age, adjusted for 
other imputed covariates, were estimated using multivariate logistic regressions. As a 
sensitivity analysis, the analysis was repeated including both imputed and passive covariates. 
Covariates for models were not selected based on significance (i.e. p-value cutoff).  The odds 
ratios for 30 day mortality with age within LV function strata, and for LV function within age 
strata, were estimated using a multivariate logistic regression.  Formal testing of the Age#LV 
function (binary operator to specify interactions) and age##LV function (binary operator to 
specify factorial interactions) interactions were explored using interaction terms which were 
added to these models.  Addition analysis was performed to evaluate the use of beta-blockers 
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and angiotensin converting enzyme inhibitor at discharge among patients with poor LV 
function according to age group.  
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Results 
 A total of 424,848 patients with ACS were recorded in the MINAP registry between 
2006 and 2010.  LV function data was only available for 123,609 participants. After multiple 
imputations, we were able to impute missing values for LV function and the imputed dataset 
had 414,305 participants. After controlling for potential confounders a total of 339,887 
patients were included in the regression models. The flow chart of participant inclusion is 
shown in Supplementary Figure 1.  Supplementary Table 2 shows the baseline characteristics 
of participants according to whether LV function data is available. 
 The characteristics of the study cohort according to LV function based on ejection 
fraction categories are shown in Table 1. The majority (54%; n=223,293) of the cohort had 
good LV function (ejection fraction ≥50%), whilst 33% (n=136,009) had moderate LV 
function and 13% (n=55,003) had poor LV function. Patients with poor LV function were 
significantly older and were more likely have several co-morbidities including hypertension, 
prior myocardial infarction, prior angina, heart failure, stroke, COPD, renal failure, diabetes 
and peripheral vascular disease.  For medication use prior to admission, there was a greater 
usage of medications with decreasing LV function. Whilst use of all medications was higher 
on discharge than at admission for all categories of LV function, there was a greater use of 
medication in patients with good LV function, with usage of medications differing 
significantly across categories of LV function.  Crude mortality at 30 days was 7%, 9% and 
17% for good, moderate and poor LV function, respectively. 
 The percentages of patients with poor LV function in each age groups were 8.1%, 
13.1%, 17.3% and 20.1% for the age groups <65, 65-74.9, 75-84.9 and ≥85 years, 
respectively  (Figure 1).   
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 The crude mortality at 30 days by LVEF categories and age group is shown in Table 2 
and Figure 1.  The highest mortality was observed in those with the oldest age and poorest 
ejection fraction.   
 Table 2 shows the association of age group and LV function on the chances of 30-day 
mortality after adjustments for potential confounders. Within an age group, worsening LV 
function was associated with higher odds of death.  For those aged <65 years, the adjusted 
odds of death comparing poor versus good function was 2.11 (95% CI 1.88-2.3), whilst the 
corresponding results for patients in the age group ≥85 years was 1.28 (95% CI 1.20-1.36).  
The odds for 30-day mortality within each LV function group attenuated with older age.  
When analyzed within each LV function strata, in those with good LV function, there was a 
higher risk of death if aged ≥85 years (OR 5.89 (95% CI 5.44-6.37)) compared to those aged 
<65 years (OR 1.00), the corresponding value for poor LV function in ≥85 years group was 
OR 3.43 (95% CI 3.11-3.78).  Further analysis using age and LV interaction terms in the 
model only attenuated the results and all interaction terms were significant (Table 2). 
 The use of beta-blockers and angiotensin converting enzyme inhibitors at discharge 
among patients with poor LV function stratified by age group is shown in Table 3.  Older 
patients had reduced receipt of both beta-blocker and angiotensin converting enzyme 
inhibitors (60% and 62% respectively compared to 80% and 84% in the youngest age group). 
Sensitivity analysis was performed considering additional passive variables in multivariate 
model for analysis of 30-day mortality according to age group (Data not shown).  In general 
additional adjustments for passive variables as well as imputed variables led to similar 
results.
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Discussion 
 In this study, we found that worse LV function post ACS is associated with increased 
30-day mortality, and that the association of increased mortality with worsening LV function 
attenuates with increased age.  We show that the prevalence of LV dysfunction in ACS 
patients is significant, from 8.1% in younger patients to 20.1% in older patients.  Finally, we 
found that older ACS patients with poor LV function are less likely to receive evidence based 
therapy recommended by current ESC and AHA guidelines such as angiotensin converting 
enzyme inhibitors and beta-blockers.   
 We report for the first time that there is less adverse prognostic association between 
worsening LV function and mortality outcomes in older patients compared to younger 
patients. This novel observation may relate to a higher co-morbid burden within the older 
cohort that would increase mortality rates irrespective of LV function. While we attempted to 
adjust for a wide range of co-morbid conditions recorded in the MINAP dataset systematic 
measures of co-morbidity such as the Charlson Co-morbidity Index that have been shown to 
have an independent prognostic impact  in a variety of cardiovascular diseases20-23 are not 
recorded in the MINAP registry hence the possibility of residual confounding remains. For 
example, a recent report from the Swiss AMIS Plus registry demonstrated that close to half of 
all patients had at least 1 co-morbid condition defined by the Charlson co-morbidity index 
and that the Charlson index was a independent predictor of in-hospital and 1 year mortality.20 
Unmeasured prognostic factors such as dementia or frailty might affect both the receipt of 
specialist management and also eventual outcomes.  Older patients with ACS are less 
intensively investigated and are less likely to receive evidence-based therapies recommended 
by guidelines that improves the prognosis of patients with poor left ventricular function24-26  
Possible reasons for under-treatment among the elderly include increased co-morbidity and 
higher risk of complications with intensive treatment.24  There may be more uncertainty 
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regarding the true benefits of interventions for elderly patients as older patients are under-
represented in trials and there are an absence of reliable data for such patients, which in turn 
leads to more conservative management which may differ from that suggested in 
guidelines.27 
 In our contemporary ACS population, the prevalence of LV dysfunction post ACS 
remains high despite the widespread population-based use of primary prevention and 
significant advances in ACS care over the last decade, from high uptake of secondary 
prevention medication through to early precautious coronary intervention. Older studies that 
predated the use of such therapies such as the French nationwide USIC 2000 registry reported 
that 13% of participants had ejection fraction ≤35%,1  whilst in the MAGIC trial, severe 
LVEF fraction (as defined by ejection fraction <30%) was present in 5.9% of participants.7  
Therefore the current data shows that LVSD post-ACS remains highly prevalent.  
 This study has several strengths.  The study represents a contemporary national cohort 
with a large sample size and statistical power.  There is a rich case-mix which allowed us to 
capture well the relationships between predictors (LV function and age) and outcome (30-day 
mortality post-ACS). We were able to control for a variety of potential confounding factors 
which may affect mortality such as prior co-morbidities, prior coronary interventions, acute 
cardiac damage markers, medications, and management.  Moreover, our results are from a 
national registry of ACS patients so the results are highly generalisable to real-world clinical 
practice.  This cohort differs from previous work which has focused on the impact of LVEF 
in specific ACS syndromes28 or in those who underwent revascularization only.5,29 
 Our study has some limitations. There was a large degree of missing data on LVEF so 
we imputed the missing data. We observed that those who did not have LVEF recorded had 
higher mortality rates (10% vs. 6%) and were older (mean age 69.4 vs. 68.3 years). Secondly, 
we were unable to determine whether recorded LV dysfunction was due to the incident 
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infarct or was already present prior to presentation with ACS. Nevertheless, our objective 
was to examine the impact of age on the relationship between LVEF and outcome of 30-day 
mortality after an ACS, thus we were interested in the internal relationship between the 
LVEF categories and outcome post ACS regardless of the timing of onset of LV impairment. 
In addition, the primary outcome was all-cause mortality rather than cause-specific. However, 
it is most likely that the cause of death is related to the index ACS in the vast majority of 
cases.  The echocardiographic evaluation for ejection fraction is not standardized across the 
NHS, and there may also be local variations in the proportion of patients entered into MINAP 
which itself may be age-biased.   
 
Conclusions 
 We observe that whilst the prevalence of LV dysfunction increases with older age in 
patients who have had an ACS event, the prognostic significance of LV dysfunction in ACS 
diminishes with older age. We also report age related inequalities within the UK in the 
management of ACS, in that older patients with ACS are less likely to receive evidence based 
treatments for LV dysfunction. Finally, 50% of patients in this registry have missing LV 
function data despite evidence to suggest that LV function has an important prognostic 
impact post ACS and assessment of LV function in ACS is recommended by all national and 
international guidelines. Future studies investigating those factors that can predict outcomes 
more accurately in older people with ACS are also warranted for planning of appropriate 
management in this age group. Efforts should also be made to better understand and address 
the reasons why older people are under-treated for their poor LV function after an ACS. 
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Table and Figure Legends 
Table 1: Baseline characteristics of the MINAP cohort by LV function 
 
Table 2: Crude deaths at 30 days, odds of death at 30 days and age group and LV function 
interaction terms among ACS patients by LV function and age group  
 
Table 3: Evaluation of use of beta-blockers and angiotensin converting enzyme inhibitors on 
discharge among patients with poor LV function group 
 
Figure 1: Age group and prevalence of poor LV function and mortality rate according to age 
group and LV function 
 
Supplementary Figure 1: Flow chart of analysis cohort and comparison of included and 
exclude participants 
Supplementary Table 1: Baseline characteristics of participants with missing and no 
missing LV function data  
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Table 1: Baseline characteristics of the MINAP cohort by LV function 
 
Variable†‡ Good LV function 
≥50% (n=223,293) 
Moderate LV function 
30-49% (n=136,009) 
Poor LV function 
<30% (n=55,003) 
p-value‡ 
Mean age (years) 67.0 (±14.3) 70.8 (±13.6) 74.1 (±12.8) <0.001 
Male (%) 143,660/223,293 (64%) 89,628/136,009 (66%) 36,522/55,003 (66%) <0.001 
Current or ex-smokers 140,117/223,293 (63%) 85,243/136,009 (63%) 34,175/55,003 (62%) 0.026 
Mean systolic blood pressure (mmHg) 141 (±29) 138 (±29) 130 (±28) <0.001 
Peak troponin 
Median Troponin I (IQR) (µg/L) 
Median Troponin T (IQR) (µg/L) 
Mean Troponin I (SD) (µg/L) 
Mean Troponin T (SD) (µg/L) 
 
0.37 (0.09-1.56) 
2.1 (0.2-12.1) 
2.8 (±11.3) 
11 (±20) 
 
0.53 (0.12-2.30) 
3.7 (0.4-21.8) 
4.0 (±15.2) 
17 (±27) 
 
0.44 (0.11-1.97) 
5.2 (0.9-27.7) 
3.9 (±14.9) 
15 (±27) 
 
 
 
Comorbidities  
Hyperlipidemia 80,396/223,293 (36%) 47,014/136,009 (35%) 18,697/55,003 (34%) <0.001 
Hypertension 111,468/223,293 (50%) 69,032/136,009 (51%) 28,230/55,003 (51%) <0.001 
Prior myocardial infarction 47,800/223,293 (21%) 42,218/136,009 (31%) 23,557/55,003 (43%) <0.001 
Prior angina 65,148/223,293 (29%) 45,109/136,009 (33%) 23,311/55,003 (42%) <0.001 
Prior heart failure 6,248/223,293 (3%) 9,656/136,009 (7%) 10,609/55,003 (19%) <0.001 
Stroke 16,303/223,293 (7%) 13,194/136,009 (10%) 7,319/55,003 (13%) <0.001 
COPD 32,483/223,293 (15%) 21,360/136,009 (16%) 10,520/55,003 (19%) <0.001 
Renal disease 8,265/201,790 (4%) 7,740/122,903 (6%) 5,152/49,404 (10%) <0.001 
Diabetes 38,298/223,293 (17%) 29,936/136,009 (22%) 15,072/55,003 (27%) <0.001 
PVD 8,329/223,293 (4%) 7,294/136,009 (5%) 4,202/55,003 (8%) <0.001 
Prior PCI 23,299/223,293 (10%) 14,928/136,009 (11%) 6,291/55,003 (11%) <0.001 
Prior CABG 12,391/223,293 (6%) 11,224/136,009 (8%) 5,343/55,003 (10%) <0.001 
Medications prior to admission  
ACE inhibitor 78,775/223,293 (35%) 53,672/136,009 (39%) 26,098/55,003 (47%) <0.001 
Beta blocker 66,095/223,293 (30%) 45,067/136,009 (33%) 20,389/55,003 (37%) <0.001 
Statin 95,434/223,293 (43%) 63,334/136,009 (47%) 29,772/55,003 (54%) <0.001 
Aspirin 58,585/223,293 (26%) 40,800/136,009 (30%) 19,327/55,003 (35%) <0.001 
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Clopidogrel 41,234/223,293 (18%) 28,712/136,009 (21%) 13,553/55,003 (25%) <0.001 
Diagnosis at current admission <0.001 
NSTEMI or unstable angina 125,931 (62%) 74,961 (60%) 33,086 (67%)  
STEMI 77,115 (38%) 50,801 (40%) 16,658 (33%)  
Medications at discharge  
ACE inhibitor 172,358/223,293 (77%) 109,731/136,009 (81%) 41,490/55,003 (75%) <0.001 
Beta blocker 168,960/223,293 (76%) 104,114/136,009 (77%) 38,097/55,003 (69%) <0.001 
Statin 202,338/223,293 (91%) 123,667/136,009 (91%) 46,005/55,003 (84%) <0.001 
Aspirin 201,177/223,293 (90%) 122,359/136,009 (90%) 45,697/55,003 (83%) <0.001 
Clopidogrel 174,571/223,293 (78%) 104,706/136,009 (77%) 36,234/55,003 (66%) <0.001 
Angiography performed  
Angiography 135,370/223,293 (61%) 69,101/136,009 (51%) 19,147/55,003 (35%) <0.001 
Mortality outcomes     
Mortality at 30 days 14,129/216,094 (7%) 12,477/132,095 (9%) 9,046/53,444 (17%) <0.001 
† Results reported as mean (SD) for continuous variables and n (%) for categorical variables.   
‡ Oneway analysis of variance (continuous variables), Chi2 square test (categorical variables). 
BMI=body mass index, COPD=chronic obstructive pulmonary disease, PVD=peripheral vascular disease, PCI=percutaneous coronary 
intervention, CABG=coronary artery bypass graft 
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Table 2: Crude deaths at 30 days, odds of death at 30 days and age group and LV function interaction terms among ACS patients by LV 
function and age group  
 
2a) 
 
 
 
 
 
 
 
 
 
2b)  
Age group Good LV function 
≥50% (reference) 
Moderate LV function 
30-50% (95% CI) 
Poor LV function <30% 
(95% CI) 
p-value 
Age < 65 years 1.00  1.25 (1.13-1.38) 2.11 (1.88-2.37) <0.001 
Age 65-74 years  1.00 1.18 (1.09-1.27) 1.62 (1.48-1.77) <0.001 
Age 75-84 years  1.00 1.12 (1.05-1.19) 1.40 (1.30-1.51) <0.001 
Age ≥85 years 1.00 1.08 (1.02-1.15) 1.28 (1.20-1.36) <0.001 
 
LV function strata Age < 65 years 
(reference) 
Age 65-74 years 
(95% CI) 
Age 75-84 years 
(95% CI) 
Age ≥85 years 
(95% CI) 
p-value 
Good LV function ≥50% 1.00  2.54 (2.35-2.73) 4.28 (3.94-4.65) 5.89 (5.44-6.37) <0.001 
Moderate LV function 30-50% 1.00 2.27 (2.09-2.48) 3.62 (3.31-3.94) 4.86 (4.44-5.33) <0.001 
Poor LV function <30% 1.00 1.90 (1.70-2.13) 2.73 (2.47-3.03) 3.43 (3.11-3.78) <0.001 
Sample size for age group according to LV function, sample for LV function by age group small because estimation samples vary.  Adjusted for 
age, sex, smoking status, systolic blood pressure, troponin, hyperlipidaemia, hypertension, previous myocardial infarction, angina, previous heart 
failure, previous stroke, COPD, diabetes, peripheral vascular disease, previous PCI, previous CABG, previous ACEi use, previous beta-blocker 
Variable Good LV function 
≥50% (n=216,094) 
Moderate LV function 
30-49% (n=132,095) 
Poor LV function 
<30% (n=53,444) 
p-value for 
difference between 
groups 
Death at 30 days 
Age <65 years 
Age 65-74 years 
Age 75-84 years 
Age ≥85 years 
 
1,914/94,265 (2.0%) 
2,596/49,958 (5.2%) 
5,090/47,884 (12.9%) 
4,529/23,987 (18.9%) 
 
1,229/42,662 (2.9%) 
2,148/31,687 (6.8%) 
4,712/36,674 (12.9%) 
4,388/21,072 (20.8%) 
 
802/12,007 (6.7%) 
1,541/12,348 (12.5%) 
3,601/17,748 (20.3%) 
3,102/11,341 (27.4%) 
 
<0.001 
<0.001 
<0.001 
<0.001 
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use, previous statin use, previous aspirin use, discharge ACEi use, discharge beta-blocker use, discharge statin use, discharge aspirin use, 
admission ward and receipt of angiography. 
 
2c) 
 
Interaction terms Age < 65 years Age 65-74 years 
(95% CI) 
Age 75-84 years 
(95% CI) 
Age ≥85 years 
(95% CI) 
Good LV function ≥50% 1.00 (reference) 2.38 (2.20-2.58) 4.10 (3.78-4.44) 5.76 (5.33-6.24) 
Moderate LV function 30-50% 1.26 (1.12-1.41) 2.79 (2.53-3.08) 4.53 (4.16-4.92) 6.07 (5.60-6.58) 
Poor LV function <30% 2.46 (2.16-2.79) 4.22 (3.80-4.70) 5.67 (5.22-6.17) 6.86 (6.24-7.53) 
 
Model with interactions terms Age < 65 years 
(reference) 
Age 65-74 years 
(95% CI) 
Age 75-84 years 
(95% CI) 
Age ≥85 years 
(95% CI) 
Age group 1.00 2.38 (2.20-2.58) 4.10 (3.78-4.44) 5.76 (5.33-6..24) 
 
Model with interactions terms Good LV function 
≥50% (reference) 
Moderate LV function 30-
50% 
Moderate LV function 
30-50% 
LV function 1.00  1.26 (1.12-1.41) 2.46 (2.16-2.79) 
Sample size for age group according to LV function, sample for LV function by age group small because estimation samples vary.  Adjusted for 
age, sex, smoking status, systolic blood pressure, troponin, hyperlipidaemia, hypertension, previous myocardial infarction, angina, previous heart 
failure, previous stroke, COPD, diabetes, peripheral vascular disease, previous PCI, previous CABG, previous ACEi use, previous beta-blocker 
use, previous statin use, previous aspirin use, discharge ACEi use, discharge beta-blocker use, discharge statin use, discharge aspirin use, 
admission ward and receipt of angiography.  
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Table 3: Evaluation of use of beta-blockers and angiotensin converting enzyme inhibitors on discharge among patients with poor LV function 
group 
 
Discharge medication Age < 65 years  Age 65-74 years  Age 75-84 years  Age ≥85 years  p-value 
Use of beta-blocker on discharge 9,946/12,468 
(80%) 
9,204/12,690 (73%) 11,981/18,207 (66%) 6,966/11,638 
(60%) 
<0.001 
Use of angiotensin receptor 
blocker on discharge 
10,491/12,468 
(84%) 
10,251/12,690 (81%) 13,483/18,207 (74%) 7,265/11,638 
(62%) 
<0.001 
P-values based on Chi2 square test. 
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Supplementary Figure 1: Flow chart of analysis cohort and comparison of included and exclude participants 
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Supplementary Table 1: Baseline characteristics of participants with missing and no missing LV function data   
Variable†‡ No missing LV 
function 
Missing LV function  p-value‡ 
Mean age (years) 68.3 (±13.8) 69.4 (±14.2) <0.001 
Male (%) 83,013/123,439 (67%) 193,532/300,711(64%) <0.001 
Current or ex-smokers 76,162/117,313 (65%) 166,720/267,427 (62%) <0.001 
Mean systolic blood pressure (mmHg) 139 (±29) 139 (±29) 0.269 
Peak troponin 
Median Troponin I (IQR) (µg/L) 
Median Troponin T (IQR) (µg/L) 
Mean Troponin I (SD) (µg/L) 
Mean Troponin T (SD) (µg/L) 
 
0.62 (0.15-2.44) 
3.7 (0.5-20.0) 
3.5 (±14.1) 
16 (±27) 
 
0.34 (0.09-1.29) 
2.2 (0.2-13.0) 
2.4 (±11.8) 
13 (±23) 
 
 
 
Comorbidities 
Hyperlipidemia 42,691/117,337 (36%) 92,394/264,650 (35%) <0.001 
Hypertension 60,453/119,709 (51%) 138,721/274,941 (50%) 0.794 
Prior myocardial infarction 28,818/119,808 (24%) 79,585/276,474 (29%) <0.001 
Prior angina 33,719/119,425 (28%) 92,195/272,246 (34%) <0.001 
Prior heart failure 7,101/119,283 (6%) 17,224/265,319 (6%) <0.001 
Stroke 9,494/119,333 (8%) 24,609/265,215 (9%) <0.001 
COPD 17,447/117,526 (15%) 41,327/260,696 (16%) <0.001 
Renal disease 6,628/119,325 (6%) 14,998/265,299 (6%) 0.219 
Diabetes 24,327/121,471 (20%) 57,019/283,341 (20%) 0.481 
PVD 5,797/116,608 (5%) 11,954/259,614 (5%) <0.001 
Prior PCI 10,615/118,848 (9%) 30,466/269,881 (11%) <0.001 
Prior CABG 7,257/119,107 (6%) 19,557/270,703 (7%) <0.001 
Medications prior to admission 
ACE inhibitor 42,353/115,278 (37%) 96,592/246,762 (39%) <0.001 
Beta blocker 33,289/115,339 (29%) 82,343/247,095 (33%) <0.001 
Statin 50,255/117,476 (43%) 120,051/255,022 (47%) <0.001 
Aspirin 31,898/117,286 (27%) 77,116/263,388 (29%) <0.001 
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Clopidogrel 8,382/59,590 (14%) 35,726/161,953 (22%) <0.001 
Diagnosis at current admission 
NSTEMI or unstable angina 67,716 (58%) 172,722 (64%)  
STEMI 49,612 (42%) 98,710 (36%)  
Medications at discharge 
ACE inhibitor 86,753/103,845 (84%) 168,845/221,285 (76%) <0.001 
Beta blocker 82,526/104,280 (79%) 164,523/223,156 (74%) <0.001 
Statin 97,282/104,608 (93%) 200,082/225,003 (89%) <0.001 
Aspirin 96,062/104,935 (92%) 199,740/226,351 (88%0 <0.001 
Clopidogrel 42,317/53,610 (79%) 104,947/143,110 (73%) <0.001 
Angiography performed  
Angiography 54,666/88,871 (62%) 104,448/215,945 (48%) <0.001 
Mortality outcomes    
Mortality at 30 days 6,792/118,703 (6%) 29,023/293,153 (10%) <0.001 
† Results reported as mean (SD) for continuous variables and n (%) for categorical variables.  ‡ Oneway analysis of variance (continuous 
variables), Chi2 square test (categorical variables). 
BMI=body mass index, COPD=chronic obstructive pulmonary disease, PVD=peripheral vascular disease, PCI=percutaneous coronary 
intervention, CABG=coronary artery bypass graft  
 
